Director of Research at INSERM

Research Unit in Nancy, France: INSERM UMR U1122; IGE-PCV (Interactions Géne-Environement en Physiopathologie Cardio-Vasculaire) at the University of Lorraine and of a BRC (Biological Resources Center), the BRC IGE-PCV.
Sofia Siest’s main research interests are in the domain of public health, personalised medicine, prevention, genetic epidemiology, genomics and pharmacogenomics, cardio-vascular diseases, VEGF and inflammation.
She has published more than 350 papers in international scientific committee journals (index h: 50, citations: 11419), 2 patents and gave more than 80 international conferences under invitation.

Member: European Society of Pharmacogenomics and Personalised Therapy

University of Turku, Finland Institute of Biomedicine
Adjunct Professor

Phd in Interdisciplinary Medical Sciences (2011) and habilitation in Molecular Genetics (2015).
Professional experience is ranging from early phase research until clinical application published in leading international scientific journals (Cell, Nature Genetics, Clinical Cancer Research) and patented.
Research interest is focused on precision medicine and pharmacogenomics of cancer, with the main line and mission to enable prostate cancer treatment and new drug discovery via innovative genomic biomarkers.
Interested how artificial intelligence and machine learning will transform healthcare. Additional activities as HORIZON2020, Innovative Medicines Initiative (IMI) expert, advisor, editor in scientific journal.

Member: European Society of Pharmacogenomics and Personalised Therapy (ESPT Board)
European Society of Human Genetics (ESHG)
Finnish Society of Clinical Genetics (FSCG)
Finnish Society of Clinical Pharmacology (FSCP)
Turku Cancer Research Society (TCRS Board)


University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia
Full Professor of Clinical Biochemistry, PI in genetics of complex disorders

Full professor of Clinical Biochemistry, coordinator of PhD program of Clinical Biochemistry at University of Ljubljana and principal coordinator of the CEEPUS CIII-SI-0611 network of student exchange program. Her research is focused on genetic backgrounds of complex diseases like osteoporosis, osteoarthritis, insulin resistance, obesity (metabolic syndrome), etc. After genotype-phenotype association studies her group continued to functional evaluation of genetic variations using primary and mesenchymal stem cell models. She is the member of four international consortiums and is the partner in the Interreg IT-SLO EU-project ARTE (2017-2020). Her bibliography consists of over 120 scientific papers (h-index=21) and is the member of editorial boards of five international scientific journals. For her contribution to development of laboratory medicine profession in Slovenia she received the Recognition from SACCLM in 2016.

Member: SACCLM, EFLM, ECTS, ESPT

Thermo Fisher Scientific
Associate Director, Business Development Genetic Sciences Division

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer.
In my role as Associate Director business development within the Genetic Science Division, I am focusing on the development and introduction of novel solutions for the Healthcare market. This includes solutions for pharmacogenomics testing, infectious disease testing as well as novel screening tools for the oncology market. I am ESPT board member, representing the ESPT Corporate members.

Member: European Society of Pharmacogenomics and Personalised Therapy

Dr. Adrián LLerena Ph.D. is the Director of the Clinical Research Center in the University Hospital in Badajoz Spain. He is also professor of Pharmacology and Clinical Pharmacology in the Medical School of the University of Extremadura, between 1989-1993 he did his post doc at Karolinska Institute Sweden focusing on Clinical Pharmacogenetics. His teaching experience is of more than 20 years in Spain and of about 9 years in Portugal. He has supervised more than 10 Ph.D. theses so far. He has also been an invited professor in different Universities in USA such as University of California at Los Angeles 2004 Mount Sinai Medical School at NY 2005 and Miller Medical School at Miami 2006 and in Latin America such as UNAM in Mexico San Marcos in Peru, Chile UFMG Brasil, Australian National University in Camberra etc. He has published more than 150 peer reviewed papers and book chapters. He is also coordinating the Iberoamerican network of Pharmacogenetics since 2006. He served in different Scietific societies as IberoAmerican Society of Pharmacogenomics. He has been principal investigator in more than 30 national and european research projects. He has also served as reviewer in all journals related to clinical pharmacology and mainly pharmacogenetics and clinical psychopharmacology. He has organized several national and international workshops and Scientific conferences in Spain and Latin America. Currently he is Vicepresident of the Spanish Society of Pharmacogenetics and Pharmacogenomics and Vicepresident of the Spanish Society for Clinical Pharmacology. Since 2010 he is a member of the EMA Pharmacogenomics Working Parthy

University of Kiel, Germany
Full Professor of Pharmacology

Graduation in biochemistry and in medicine, Free University Berlin. Dr. rer. nat. (PhD) in 1989, specialization in clinical pharmacology at Charité Berlin (1998), Dr. med. (MD) in 1999. Habilitation in Clinical Pharmacology 2000, Professor of Pharmacology and Toxicology, University of Greifswald (2000-2004). Since 2004 Professor of Pharmacology and Director Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein. Since 2012 Dean of Education, Medical Faculty. Research is focused on pharmacogenomics and -epigenomics of drug metabolizing enzymes and transporters, mechanisms of drug resistance, drug-drug interactions as well as neuropathic pain research. Activity on various editorial boards, learned societies and advisory boards.

Member: AACR, AGAH, ASCPT, BPS (Fellow), DGK, DGKliPha (Chairman), DIVI, ESPT (Executive Board), IUPHAR (President)

  • University of Geneva, Faculty of Medicine, Department of Pediatrics, Professor Associate
  • Geneva University Hospital, Children and Adolescents Department, Division of Pediatric Onco-Hematology, Head of Unit
  • University of Geneva, Faculty of Medicine, Department of Pediatrics, Pediatric Hematology and Oncology Research Platform, CANSEARCH Research Laboratory, Director

Since 2014, he has been a member of the European Pediatric Group of Blood and Marrow Transplantation and chair of the clinical trial committee as well as board member of the European Society of Pharmacogenomics and Individualized Therapy, chair of the scientific division. In 2016, he created and became Head of the Swiss Group of Pharmacogenomics and Individualized Therapy.

Prof. Marc Ansari has practiced in the medical field for over 19 years, particularly in the areas of pediatric oncology-hematology and pharmacogenetics, in Geneva and in Montreal. In 2011 he created the first pediatric hematology and oncology research platform of the Faculty of Medicine in Geneva and founded the same year the CANSEARCH Foundation in order to support its activities. Since January 2013, he is Head of the Pediatric Onco-Hematology Unit of the Geneva University Hospital (HUG). In November 2015, he was appointed Professor Assistant at the Faculty of Medicine of Geneva, and, in October 2018, Professor Associate.

Member:  Swiss Association of Medical Assistants and Heads of Clinics, Swiss Society of Pediatrics, American Society of Hematology, International Society of Pediatric Oncology, Swiss Society of Pediatric Oncology, French Society of Childhood Tumors, French Society of Transplantation, Swiss Medical Association, Swiss Hemophilia Network, Swiss Blood Stem Cells, Children’s Cancer and Leukemia Group, German Pediatric Oncology Group.
Board Member: Pediatric Disease Working Group of European Blood and Marrow, European Society of Pharmacogenomics and Individualized Therapy, Swiss Society of Toxicology and Clinical Pharmacology, Swiss Group of Pharmacogenomics and Individualized Therapy (Founder and Director), DNA germline SPOG Working group (chairman), Children’s Hepatic tumors International Collaboration (CHIC-SIOPEL).

General Secretary

Summary to be provided

Treasurer

Sapienza University of Rome – University Hospital Sant’Andrea Rome
Full professor in Molecular Biology – Director of Analytical Laboratory – Clinical Biochemistry  Unit

Academic career:
1988-1994 Researcher at  National Research Council, Center of Molecular Biology
1994-2000 Full professor of Biochemistry, Faculty of Medicine, University of Chieti, Italy
1998-2000 Director of the Specialty School in Laboratory Medicine, University of Chieti
2000-2003 Full professor of Biochemistry, II Faculty of Medicine, Sapienza University of Rome
2003-present Full professor of Molecular Biology,  Faculty of Medicine and Psychology, Sapienza University of Rome

Clinical career:
2003-2017 Director of the Advanced Molecular Diagnosis Unit (DiMA),  Sant’Andrea Hospital, Sapienza University of Rome 2017- present Director of Analytical Laboratory – Clinical Biochemistry  and Advanced Molecular Diagnostics,  Sant’Andrea University Hospital, Sapienza University of Rome

Member: Italian Foundation Personalized Medicine – ESPT

President Elect

Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece – Clinical Pharmacology and Pharmacoenetics Unit, Academic General Hospital of Evros, Alexandroupolis, Greece.
Director and Professor of Pharmacology, Pharmacogenomics, and Precision Medicine

Prof. Manolopoulos obtained a PhD from the Medical School of Patras University in 1991. Between 1992 and 1995 he was a postdoctoral researcher at the Milwaukee Clinical Campus of the University of Wisconsin. Then he took a post as senior research scientist at the Medical School of the Katholic University in Leuven, Belgium, between 1995 and 1998. Since 1998 Dr Manolopoulos has been in a faculty member in Alexandroupolis teaching basic and clinical pharmacology to medical students. Also, since 2001 he has developed and teaches a course in Pharmacogenetics (since 2015 renamed to Pharmacogenomics and Personalised medicine), one of the first to be introduced to the Medical School undergraduate curriculum worldwide. He has authored more than 115 indexed publications that have received more than 2900 citations, h# 30 (Scopus), including 3  in New England Journal of Medicine, in one of which he was the corresponding author (NEJM 369:2304, 2013). His current interests include research and clinical applications of pharmacogenomics and epigenetics in drugs used in anticoagulation, diabetes, psychiatry, and oncology. In addition he has a long-standing interest in endothelial cell physiology and atherosclerosis. He has received funding for his research from national and international funding bodies. He directs a Masters’ Course in Clinical Pharmacology and Therapeutics and heads the Research Committee of his Medical School. He is the president of the Greek Society for Basic and Clinical Pharmacology and also participates in the Executive Committee of the European Association for Clinical Pharmacology (EACPT). He is the President-elect of ESPT.